Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Summary

RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related malignancies.

Conditions

• Lung Cancer
• Lymphoma

Interventions

GENETIC

DNA analysis

This sample will be used for germline DNA analysis.

GENETIC

RNA analysis

RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.

GENETIC

gene expression analysis

Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.

GENETIC

polymorphism analysis

Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.

OTHER

biologic sample preservation procedure

Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.

OTHER

flow cytometry

Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.

OTHER

medical chart review

Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• The Emmes Company, LLC

  collaborator INDUSTRY

• AIDS and Cancer Specimen Resource

  collaborator OTHER

• University of Arkansas

  collaborator OTHER

• AIDS Malignancy Consortium

  lead NETWORK

Principal Investigators

• Lee Ratner, MD, PhD · Washington University Siteman Cancer Center

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-01-02

Primary Completion

2022-01-14

Completion

2022-01-14

Countries

• United States

Study Locations